AZTA
Fiscal year ends September Quarters are offset from the calendar — Q1 is Oct–Dec

Azenta, Inc. is a provider of biological and chemical compound sample exploration and management solutions for the life sciences industry. The company operates through two main segments: Sample Management Solutions and Multiomics. Its Sample Management Solutions portfolio includes automated storage systems, cryogenic systems, sample repository services, consumables, and informatics software. The Multiomics segment offers genomic services, including gene sequencing and gene synthesis. Azenta serves pharmaceutical and biotechnology companies, research hospitals, academic institutions, and government agencies in North America, Asia, and Europe. The company was founded in 1978 and formerly operated as Brooks Automation, Inc. before changing its name in December 2021. It divested its semiconductor automation business in 2022 to focus solely on life sciences. Notable products and services include BioArc Ultra automated storage, Mirage Connect sample tracking, Limfinity laboratory information management, and CryoArc cryogenic storage systems.

Summarised from the company's own disclosures, fiscal year ended Dec 2025

Industry Medical Instruments & Supplies Homepage azenta.com
Sector Healthcare IR page investors.azenta.com
Tags
sample management, cryogenic storage, automated storage, genomic services, gene sequencing, gene synthesis, biobanking, cold chain logistics, laboratory informatics, life sciences, BioArc Ultra, Mirage Connect, Limfinity, CryoArc Vita-76, Barkey Controlled Rate Thawing, GENEWIZ, Azenta Sample Storage Tubes, Cryo Monitoring Portal, B Medical Systems
Press page investors.azenta.com/news-releases

Metrics

Valuation  
Market cap $ 1.527B
Market cap (USD) $ 1.527B
P/E -14.42
PEG —
P/BV 1.01
P/S 2.49
P/OCF 40.21
P/FCF 154.53
Dividend yield 0.29%
Turnover / mcap —
Returns  
ROE -3.2%
ROI -3.9%
ROIC -1.4%
Profit margin -9.4%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) -77.4%
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 14
Quality score -33.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 593.821M 656.323M 665.072M 555.498M 513.703M 897.273M 780.848M 631.56M 692.885M 560.323M 552.708M 482.848M 450.952M 519.451M 688.105M 592.972M 218.706M 526.366M 743.258M 692.87M 463.746M 539.769M 343.61M 304.254M 381.716M 321.099M
Net profit -55.763M -164.17M -14.257M 2.133B 110.747M 64.853M 437.416M 116.575M 62.612M -69.476M 14.221M 31.361M -2.215M 136.789M 128.352M 58.982M -227.858M -235.946M 151.472M 25.93M -10.057M 17.721M -185.76M -719.954M -29.66M 12.753M
Free cash flow 38.324M 12.897M -21.946M -539.481M 97.052M -2.058M 67.037M 61.177M 83.547M 26.699M 27.581M 48.263M 50.754M 27.385M 81.195M 24.4M -67.833M -9.783M 52.255M 47.238M 19.41M 652K -62.14M -79.319M -32.967M -26.898M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 28.72 48.44 50.19 42.86 102.35 46.26 37.03 35.03 30.36 13.61 11.71 10.51 9.31 8.04 7.54 — — — — — — — — — — —
Price performance 12m -0.41 -0.03 0.17 -0.58 1.21 0.25 0.06 0.15 1.23 0.16 0.11 0.13 0.16 0.07 — — — — — — — — — — — —

Filed figures

Figure Sep 2016 Sep 2017 Sep 2018 Sep 2019 Sep 2020 Sep 2021 Sep 2022 Sep 2023 Sep 2024 Sep 2025
Balance sheet detail
Trade receivables (USD) 106M 121M 125M 166M 188M 120M 164M 157M 173M 142M
↳ YoY growth +23.0% +13.6% +3.6% +32.3% +13.7% -36.3% +36.6% -4.4% +10.3% -17.7%
↳ 5y CAGR +6.8% +8.9% +10.1% +15.6% +16.8% +2.4% +6.3% +4.6% +0.8% -5.5%
Borrowings, current (USD) — — 2M 829,000 827,000 — — — — —
Borrowings, non-current (USD) — — 194M 50.3M 49.6M 49.7M — — — —
Lease liabilities (USD) — — — 27.1M 40.4M 50.7M 56.2M 72M 70.7M 59.9M
Cash and deposits (USD) 85.1M 102M 198M 302M 296M 227M 658M 679M 311M 280M
Intangible assets (USD) 81.8M 83.5M 100M 251M 218M 187M 178M 294M 248M 102M
Right-of-use assets (USD) — — — 28.1M 39.1M 49.7M 54.1M 66.6M 64M 54M
Net debt (borrowings + leases - cash) (USD) — — -1.64M -250M -205M -127M — — — —
Cash flow detail
Operating cash flow (USD) 39.5M 96.2M 74M 90.9M 37.9M 150M -466M 17.5M 50.3M 72.2M
Purchases of property, plant and equipment (USD) -12.8M -12.7M -12.8M -23.9M -39.9M -52.8M -73.4M -39.4M -37.4M -33.9M
Purchases of intangible assets (USD) — -240,000 — — — — -4M 0.00 0.00 —
Change in receivables (cash effect) (USD) -1.8M -11.2M -28.5M -11.4M -18.8M -69.6M -31.4M 34M -11.6M 21M
Change in inventories (cash effect) (USD) 8.57M -12.8M -24.4M -2.93M -13.1M -50.4M -66.6M 8.25M 16.4M -2.67M
Change in payables (cash effect) (USD) -5.14M 7.85M 5.46M 4.7M 792,000 31M -3.93M -14.7M 9.2M 1.04M
Dividends paid (cash effect) (USD) -27.5M -27.9M -28.3M -28.9M -29.5M -29.7M -7.49M 0.00 0.00 —
Share buybacks (cash effect) (USD) — — — — — — 0.00 -839M -662M 0.00
Interest paid (cash effect) (USD) -114,000 -200,000 -6.54M -20.8M -2.16M -1.44M -469,000 0.00 0.00 —
Income taxes paid (cash effect) (USD) -4.93M -8.14M -21.1M -17M -102M -38M -452M -43.1M -2.7M -6.57M
Share-based compensation (USD) 11.7M 17.3M 19.8M 20.1M 16.3M 27.5M 10.7M 9.38M 14.5M 20.9M
Operating cash flow before change in receivables (USD) 41.3M 107M 102M 102M 56.6M 220M -435M -16.5M 61.9M 51.1M
Free cash flow (OCF - PPE - intangibles) (USD) 26.7M 83.3M 61.2M 67M -2.06M 97.1M -543M -21.9M 12.9M 38.3M
Income detail
Research and development expense (USD) 51.5M 47M 46.9M 56.4M 59.1M 22.4M 27.5M 34M 33.5M 30.4M
↳ 5y CAGR +5.3% -0.2% -0.9% +1.4% +2.5% -15.3% -10.1% -6.3% -9.9% -12.4%
Total comprehensive income (USD) 9.27M 62.7M 115M 427M 83.3M 108M 2.03B 7.23M -115M -64.5M
Comprehensive income to owners (USD) -60.2M 62.7M 115M 427M 83.3M 108M 2.03B 7.23M -115M -64.5M
Provision for credit losses (USD) — — — 3.33M 4.6M 3.45M 3.54M 8.85M 7.25M 3.75M
Credit cost ratio (credit losses / average receivables) (%) — — — 2.3% 2.6% 2.2% 2.5% 5.5% 4.4% 2.4%
Reported Nov 29, 2016 Nov 17, 2017 Nov 29, 2018 Nov 24, 2021 Nov 24, 2021 Nov 24, 2021 Nov 27, 2024 Nov 27, 2024 Nov 27, 2024 Dec 4, 2025

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

•Q4'26 reported revenue growth of 5% year over year and 2% on an organic basis

•FY'26 reported revenue growth of 5% year over year and 2% on an organic basis

•FY'27 reported revenue expected to range from $648 to $660 million

•FY'27 organic revenue growth expected to range between 3% to 5% year over year

•FY'27 adjusted EBITDA margin expected to expand approximately 200 to 250 basis points year over year

BURLINGTON, Mass., November 10, 2026 (PR Newswire) – Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the fourth quarter and fiscal year ended September 30, 2026.

B Medical Systems is reported as discontinued operations, with its historical results reflected in total diluted EPS. The Company completed the sale of the business on July 1, 2026, and received full repayment of the $35 million vendor loan, together with accrued interest, on September 3, 2026.

Exclusive licensing agreement with Elegen and acquisition of SynPlexity strengthen gene synthesis capabilities, expand high-throughput discovery workflows, and position GENEWIZ for long-term growth

BURLINGTON, Mass., Oct. 30, 2026 /PRNewswire / -- Azenta, Inc. (Nasdaq: AZTA) today announced strategic investments to advance the next phase of growth for its GENEWIZ business. Building on its trusted brand, scientific expertise, global commercial engine, and operational infrastructure, Azenta is expanding its capabilities through an exclusive licensing agreement with Elegen Corp., a developer of advanced cell-free DNA manufacturing technology, and the acquisition of SynPlexity Inc., a synthetic biology company providing high-throughput gene libraries for biological discovery.

The license agreement with Elegen brings into the GENEWIZ portfolio an innovative cell-free DNA synthesis platform designed to improve DNA quality, delivery speed, and manufacturing scalability. Its capabilities include sequence-verified DNA constructs and templates to simplify preparation for downstream experiments, including antibody discovery. The compact production workflows also enable regional capacity to be added close to customers to respond to demand as needed.

Azenta has also acquired SynPlexity, adding pooled gene assembly technology that provides thousands of full-length gene variants in a single library. These capabilities address the increasing scale of biological design by enabling researchers to efficiently build and test large numbers of candidates, including AI-generated designs.

"These strategic investments strengthen the competitive position of GENEWIZ by expanding the products and capabilities we can bring to customers and are key to accelerating our growth," said Trey Martin, President, Multiomics at Azenta. "By combining these advanced technologies with our global infrastructure and existing gene-to-antibody portfolio, we are building a differentiated platform poised to accelerate the next era of biologics discovery and development."

Since its founding in New Jersey in 1999, GENEWIZ has built a global sequencing and gene synthesis business grounded in scientific expertise, customer focus, and operational excellence. These investments complement and extend that foundation into higher-growth applications across synthetic biology, protein engineering, and AI-enabled drug discovery.

Additional details will be provided during Azenta's fourth quarter fiscal 2026 earnings call.

About Azenta Life Sciences
Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling life science organizations around the world to bring impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey.

Azenta is headquartered in Burlington, MA, with operations in North America, Europe and Asia. For more information, please visit www.azenta.com

About Elegen 
Elegen uses proprietary cell-free technologies to build longer, higher-quality DNA on a faster timeline for agricultural, chemical, healthcare, and pharma industries.

About SynPlexity 
SynPlexity is a DNA assembly technology company providing products and services centered on large, multiplexed libraries for functional screening, drug discovery, therapeutics, and other applications.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Azenta's plans to develop, integrate, manufacture and commercialize products using the licensed and acquired technologies and the anticipated benefits of the transactions, including expected improvements in gene synthesis capabilities, expansion of the GENEWIZ offerings and markets, customer adoption and demand, and financial, operational and strategic benefits. Actual results could differ materially from those expressed or implied due to risks and uncertainties, including Azenta's ability to transfer, validate, integrate and scale the technologies, achieve expected technical and commercial performance, protect relevant intellectual property and realize the anticipated benefits, as well as the risks described under "Risk Factors" in Azenta's Annual Report on Form 10-K for the fiscal year ended September 30, 2025, as updated or supplemented by subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date made, and Azenta undertakes no obligation to update them except as required by law.

INVESTOR CONTACT for Azenta Life Sciences:
Yvonne Perron
Vice President, Financial Planning & Analysis, and Investor Relations
[email protected]

Maria Isabel Cuartas
Manager, Investor Relations
[email protected]

Azenta logo

SOURCE Azenta

Azenta logo

IR Contacts

Investor Relations
[email protected]

Yvonne Perron
Vice President, Financial, Planning & Analysis and Investor Relations

Maria Isabel Cuartas
Manager, Investor Relations

Transfer Agent:
Computershare
P.O. Box 43006
Providence RI 02940-3006
Investor Center web address:
computershare.com/investor

Email Alerts

* Required Fields

* Email

©2026 Azenta, Inc. All rights reserved. | Privacy & Security Policy

NASDAQAZTA

$39.06

-2.21

Open

$39.56

Change

-$2.21(-5.35%)

Day's Range

$38.07 - $40.36

52-Week Range

$15.93 - $46.41

Volume

902.8K

Market Cap

$1.7B

Currency in USD. Quote data delayed by at least 15 minutes.

On October 28, 2026, Azenta, Inc. (“Azenta” or the “Company”) entered into a Technology, Equipment and License Agreement (the “License Agreement”) and a Master Services and Supply Agreement (the “Supply Agreement” and, together with the License Agreement, the “Elegen Agreements”) with Elegen Corp. (“Elegen”). The Elegen Agreements form an integrated commercial arrangement.

Under the License Agreement, Azenta and its controlled affiliates have acquired an exclusive, royalty-free license under Elegen’s proprietary technology, including patents and know-how relating to gene synthesis and cell-free cloning, to manufacture, market, distribute, offer to sell, sell, import and export certain gene synthesis products, and to provide those products as a service, to third-party customers worldwide, subject to the terms and conditions of the License Agreement. The arrangements are intended to support the expansion of the Company’s GENEWIZ gene synthesis capabilities and regional production capacity.

Prompts

Azenta, Inc. (ticker AZTA), listed in United States.

Company History

Date Change Detail
Dec 1, 2021 Renamed BROOKS AUTOMATION, INC. → AZENTA, INC.
May 28, 2019 Renamed BROOKS-PRI AUTOMATION INC → BROOKS AUTOMATION, INC.
May 15, 2002 Renamed BROOKS AUTOMATION INC → BROOKS-PRI AUTOMATION INC

ETFs Holding Azenta, Inc.

ETF Weight in ETF Shares Market value As of
FSCC 0.26% 28,487 $ 930.101K Aug 31, 2026
FTKI 0.25% 1,370 $ 64.691K Nov 16, 2026
FTQI 0.21% 41,855 $ 1.976M Nov 16, 2026
MSSM 0.13% 27,492 $ 897.614K Aug 31, 2026
AVSC 0.12% 79,732 $ 3.765M Nov 16, 2026
DFSV 0.08% 476,735 $ 20.91M Nov 12, 2026
RESM 0.05% 78 $ 1,990.56 Jun 30, 2026
AVUV 0.05% 351,065 $ 16.577M Nov 16, 2026
SMDX 0.03% 855 $ 40.373K Nov 17, 2026
DFAS 0.03% 203,640 $ 8.932M Nov 12, 2026
DXUV 0.01% 19,550 $ 857.463K Nov 12, 2026
DFAC 0.01% 211,131 $ 9.26M Nov 12, 2026
AVUS 0.01% 16,691 $ 788.149K Nov 16, 2026
AVSU 0.01% 1,118 $ 52.792K Nov 16, 2026
AVUQ 0.01% 620 $ 29.276K Nov 16, 2026
DCOR 0.01% 59,588 $ 2.614M Nov 12, 2026
DFUV 0.01% 18,807 $ 824.875K Nov 12, 2026
DFAU 0.00% 11,236 $ 492.811K Nov 12, 2026
DFUS 0.00% 13,038 $ 571.847K Nov 12, 2026